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Background: Double filtration plasmapheresis (DFPP) and (IA) are both used to clear antibody. However, the clinical
efficacy and safety of DFPP in patients with anti-glomerular basement membrane (anti-GBM) disease are unclear.
Methods: The 28 enrolled patients diagnosed serologically and pathologically with anti-GBM disease from 2003 to
2013 included 16 treated with DFPP and 12 with IA, with all patients administered immunosuppressive agents. DFPP
consisted of an EC50W filter for plasma separation and an EC20W filter for plasma fractionation. A double volume
of plasma was processed, and each patient received a 30–40 g human albumin supplement during each session.
IA consisted of 10 cycles per session, with 8–10 sessions performed daily or every other day and each session
regenerating 30–60 L of plasma. Serum anti-GBM antibodies and IgG were measured, and urinary and blood
tests were performed, before and after each procedure. Renal function and outcome were determined.
Results: The 28 patients consisted of 13 males and 15 females, of median age 44.5 years (range, 22.5–57 years). Six
patients had pulmonary hemorrhage and 18 had serum creatinine concentrations >500 umol/L. The average serum
creatinine concentration at early onset of disease was 525 umol/L while the peak concentration was 813 umol/L.
All patients showed progressive increases in serum creatinine and required CRRT during the course of disease.
Pathological examination showed an average 73.9% of crescents (range, 54.6–95.4%).The clinical and pathological
features of the DPPP and IA groups were similar. Efficacy of clearing anti-GBM antibody was similar in the two
groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%,
p = 0.002). One patient each had a pulmonary hemorrhage and a subcutaneous hemorrhage during treatment, but
there were no other serious complications. At the end of follow-up, patient survival and renal survival were similar in
the DFPP and IA groups.
Conclusion: DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies. The fewer
plasma-associated side effects and reduced loss of IgG suggest that DFPP may be a better treatment choice for
anti-GBM disease, especially in patients with insufficient plasma.
Keywords: Double filtration plasmapheresis (DFPP), Immunoadsorption (IA), Anti-GBM diseaseBackground
Anti-GBM nephritis is an autoimmune disorder charac-
terized by rapidly progressive glomerulonephritis and the
presence of circulating anti-glomerular basement mem-
brane (anti-GBM) antibodies. If accompanied by pulmon-
ary hemorrhage, this disease is often called Goodpasture’s
syndrome, with a high mortality rate [1,2]. Treatment* Correspondence: tang_dr@163.com
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culating antibodies. Extracorporeal removal of anti-GBM
antibody, by, for example, plasmapheresis or immunoad-
sorption (IA) is an effective treatment for Goodpasture’s
syndrome. However, lack ofimmunoadsorption column
limits the clinical applications of this method. In contrast,
double filtration plasmapheresis (DFPP) requires smaller
amounts of plasma or albumin and has been used to re-
move auto-antibodies, particularly those associated with
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Guillain-Barré syndrome, and ANCA associated vascu-
litides. Recently, DFPP was used to in several patients
with anti-GBM nephritis to remove serum anti-GBM
antibodies. To expand on these findings, we compared
the effects of DFPP and immunoadsorption (IA) on serum
anti-GBM concentrations, as well as comparing their clin-
ical efficacy in patients with anti-GBM nephritis.
Methods
Patients
Patients diagnosed with anti-GBM nephritis and hospi-
talized between December 2003 and June 2013 in the
Department of Nephrology, Jinling Hospital were con-
sidered eligible. Other inclusion criteria included a rapid
decrease in renal function, with persistent hematuria
and anuria, and an ultrasound showing normal kidney
size; positivity for serum anti-GBM antibody; the renal
biopsy showing crescentic glomerulonephritis with IF liner
IgG deposition along the glomerular basement membrane
(GBM). Clinical and pathologic data were collected from
medical records at the time of presentation and during
follow-up. Of 28 patients who underwent plasma therapy,
16 underwent DFPP and 12 underwent staphylococcal
protein A immunoadsorption. Patients with active infec-
tion, immunodeficiency, or severe cardiovascular or cere-
brovascular disease were excluded. Patients underwent
DFPP, staphylococcal protein A immunoadsorption and
renal biopsy for clinical not research purposes. All patients
or their parent/guardian provided written informed con-
sent. The study protocol was approved by Medical Ethics
Committee of Jinling Hospital.
Treatment and fellow-up protocols
All 28 patients received methylprednisolone pulse therapy,
followed by oral prednisone or mycophenolate mofetil
(MMF) or intravenous cyclophosphamide pulse therapy.
Patients showing deterioration of renal function received
maintenance hemodialysis therapy. Each patient in the
DFPP group underwent 2–4 sessions every other day. IA
was administered for 10 cycles per session, with 8–10 ses-
sions performed daily or once every other day; a total of
30–60 L of plasma was regenerated during each session.
Serum anti-GBM antibodies and serum IgG were mea-
sured after each procedure.
Follow-up data were obtained from patients’ medical
records. The primary outcomes were patient and renal
survival.
Methods of DFPP and IA
1.5 or 2 plasma volumes was processed during each DFPP
session. Two filters were used, an EC50W filter (Asahi
Kasei Corporation, Japan) as the first filter for plasma sep-
aration and the second and EC20W filter (Asahi Kasei) forplasma fractionation. Using a blood pump, native blood
was pumped into the first filter and separated into plasma
and cellular components. The second pump was used to
pump filtered plasma into the second filter, which sepa-
rated albumin from larger plasma molecules, including
immunoglobulins, immune complexes, and lipoproteins.
Low molecular weight heparin was used for anticoagu-
lants. The blood flow was set to 100 ~ 120 ml/min. During
each session, each patient received a supplement of 30–
40 g human albumin. During DFPP, waste plasma was
discarded intermittently. When the pressure on the sec-
ond filter reached the threshold value to discard plasma,
800 ml normal saline were used to flush the second fil-
ter of accumulated plasma proteins, prior to discarding
waste plasma. After each session, 200 ~ 400 ml fresh
frozen plasma was used for supplement.
IA was performed using Immunosorba PH-350 (Asahi
Kasei Medical, Tokyo, Japan). Each course of treatment
consisted of three sessions of IA. Each session was carried
out daily or every other day. Three litres of plasma was
processed at each session. Anticoagulant was the same
as DFPP. No plasma substitution was needed as the
clean plasma was returned to the patient.
Histopathology
For light microscopy, renal biopsy specimens were fixed
in 10% neutral buffered formalin, embedded in paraffin
and sectioned at 2 μm thickness. Sections were stained
with hematoxylin-eosin, periodic acid-Schiff ’s reagent,
Masson’s trichrome and periodic acid methenamine silver.
Glomerular, tubular interstitial and vascular lesions in
biopsies were recorded. Biopsy samples were evaluated
separately by two pathologists, with each blinded to the
other’s results and to patients’ data.
Statistical methods
All data were analyzed using SPSS program 16.0 for Win-
dows. Results were expressed as means ± standard devi-
ation or median, depending on whether the data were
normally distributed. Between group differences were
evaluated statistically using t-tests, whereas rates were
compared by using the Kruskal-Wallis H test or the χ2
test. A p-value <0.05 indicated statistical significance.
Results
Clinical and pathologic data
The 28 patients included 13 males and 15 females, of
median age 44.5 years (range, 9–68 years). The median
duration of disease was 5 weeks (range, 1 week–5 years).
Six patients had pulmonary hemorrhage, including one
diagnosed with diffuse alveolar hemorrhage and five with
blood-tinged sputum. Three patients were ANCA positive,
10 had anuria and 18 had a serum creatinine (SCr) con-
centration > 500 μmol/l and required renal replacement
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sion, and 17 had symptoms of gross hematuria. There
were no significant differences between the DFPP and IA
groups (Table 1).
Laboratory and pathological data are shown in Table 2.
Most patients were anemic upon admission to hospital,
19 (67.9%) had disorders of calcium and phosphorus me-
tabolism, 18 (64.3%) had high C-reactive protein (CRP)
concentrations. Except for patients with anuria, all had
abnormal findings on urinalysis, including 7 (25.0%) with
a nephrotic degree of proteinuria. Upon hospital admis-
sion, 18 (64.3%) patients had SCr levels >500 μmol/L,
with 26 (92.9%) having SCr levels >500 μmol/L during
the course of disease. NAG and RBP were also higher
than normal. Except for NAG, which was significantly
higher in the DPP than in the IA group (84.4 ± 37.3 vs.
58.1 ± 33.7, p = 0.03), none of these data differed signifi-
cantly in the two groups. At the time of biopsy, a median
73.9% (range, 54.6–95.4%) of glomeruli per patient had a
crescent shape, with 26 (92.9%) patients having >50% and
11 (39.3%) having >85% crescent-shaped glomeruli.
Effects of DFPP and IA
Removal of serum antibodies and IgG
Following the DFPP sessions, the concentration of anti-
GBM-antibody declined significantly, from 210 to 86.3
RU/ml (P < 0.01), a reduction of 123.7 RU/ml or 61.9%,
as did the concentration of IgG, from 12.4 to 4.2 g/L, a
reduction of 8.2 g/L or 62.7% (Table 3, Figure 1). Simi-
larly, the concentration of anti-GBM antibody in the IA
group declined from 199 to 57.0 RU/ml, a reduction of
142 RU/ml or 70.8%, and the concentration of IgG from
12.7 to 2.1 g/L, a reduction of 10.6 g/L or 82.5%. The
change in IgG concentration differed significantly in the
two groups (p = 0.049), whereas the change in anti-GBM
concentration did not (p = 0.452).Table 1 Baseline demographic and clinical characteristics of t
DFPP group (n = 1
Sex (Male/Female) 7/9
Age, yr 40 (21.8 ~ 50.2)
Duration of disease (wks) 5 (3 ~ 9)
Duration of kidney disease (wks) 2 (1.5 ~ 9)
Exposure to chemicals (%) 3 (18.8%)
Pulmonary hemorrhage (%) 4 (25.0%)
Smoking (%) 4 (25.0%)
Gross hematuria (%) 10 (62.5%)
Anuria (%) 8 (50.0%)
Anemia (%) 15 (93.8%)
RRT at onset (%) 5 (31.2%)
Hypertension (%) 7 (43.8%)
RRT, renal replacement therapy.Side effects of DFPP and IA
Four patients experienced fever during DFPP, one had
bleeding in the lung and one had ecchymosis in the skin.
The adverse effect rates were similar in the DFPP and
AI groups (Table 4).
Follow-up and outcome
Of the 16 patients in the DFPP group, 3 (18.8%) died at
presentation or during follow-up; four (25.0%) were lost to
follow-up; and nine (59.4%) progressed to end-stage renal
disease (ESRD), with a median renal survival of 9 weeks
(95% CI, 5–15 weeks). Five patients in this group (31.3%)
progressed to CRF, while one returned to normal, being
negative for anti-GBM antibody and on urine tests, and
an SCr range of 67–86 μmol/L. Outcomes were similar in
the two groups (Figure 2).
Discussion
To our knowledge, this study is the largest to date com-
paring these two methods of extracorporeal blood purifi-
cation in patients with anti-GBM disease, including 16
who received DFPP treatment. Although renal dysfunc-
tion and abnormal urine analysis did not improve sig-
nificantly after DFPP, serum anti-GBM-antibody titers
declined significantly, demonstrating the effectiveness of
DFPP therapy in removing these antibodies. Moreover,
the ability of DFFP to remove anti-GBM antibodies was
similar to that of IA. The two groups were also quite
similar clinically and pathologically, as well as in renal
and patient survival outcomes. None of these patients
experienced any severe side effects during treatment.
DFPP was superior to IA in reducing the loss of useful
substances and in requirements for exogenous supple-
ments owing to semi-selective removal. Reductions in
IgG concentration were lower with DFPP than with IA,
and DFPP was unrestricted, lacking an IA column.he DFPP and IA groups
6) IA group(n = 12) P
6/6 1.000
49.0 (27.5 ~ 60.3) 0.150
8 (3 ~ 10) 0.056









Table 2 Laboratory and pathological findings in the DFPP and IA groups
DFPP group (n = 15) IA group (n = 12) p
WBC (109/L) 9.39 ± 4.64 8.25 ± 3.17 0.458
Hemoglobin (g/dl) 85.4 ± 19.6 85.1 ± 13.0 0.626
Platelets (109/L) 297 ± 174 235 ± 127 0.137
Urin protein (g/24 hr) 2.85 ± 1.74 1.59 ± 1.36 0.053
Microscopic hematuria (105/ml) 2200 (950 ~ 5000) 1725 (1300 ~ 2965) 0.207
Serum albumin (g/L) 34.6 ± 4.3 35.1 ± 5.7 0.754
Serum globulin (g/L) 26.3 ± 6.7 27.1 ± 8.1 0.693
BUN (umol/L) 3.76 ± 1.44 3.12 ± 2.09 0.104
pSCr (umol/L) 826 ± 315 795 ± 437 0.430
SCr (umol/L) 551 ± 335 490 ± 445 0.353
UA (umol/L) 417 ± 188 470 ± 135 0.329
Disorders of Ca/P 12 (75.0%) 7 (58.3%) 0.218
CRP (mg/L) 25.7 (2.1 ~ 102.6) 8.8 (0.1 ~ 53.6) 0.102
High CRP 12 (75.0%) 6 (50.0%) 0.432
CD4 (n/ml) 433 ± 182 367 ± 187 0.306
CD8 (n/ml) 386 ± 233 325 ± 397 0.071
Crescent (%) 81.5 (68.1 ~ 100) 60.8 (45.8 ~ 87.9) 0.056
Cellular crescent (%) 17.4 (1.3 ~ 32.3) 14.8 (1.1 ~ 75.8) 0.536
Fibrous/ fibrocellular crescents (%) 52.25 (39.2 ~ 76.6) 41.1 (12.7 ~ 75.8) 0.538
Vascular loop necrosis 11 (68.8%) 9 (75.0%) 0.655
Bowman’s wall fracture 14 (87.5%) 11 (91.7%) 0.691
Acute interstitial lesions 2.00 ± 0.73 1.50 ± 1.24 0.251
Chronic interstitial lesions 1.88 ± 1.02 2.00 ± 0.73 0.107
Tubular atrophy 2.50 ± 0.73 2.08 ± 1.08 0.520
Interstitial cell infiltration 2.00 ± 0.73 1.50 ± 1.24 0.133
Tubulitis 1.88 ± 1.02 2.00 ± 0.73 0.675
Interstitial Fibrosis 2.50 ± 0.73 2.08 ± 1.08 0.730
Stromal vascular lesions 10 (62.5%) 7 (58.3%) 0.754
SCr, serum creatinine; BUN, bloodureanitrogen; UA, uric acid; pSCr, highest serum creatinine in the course.
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struction of the basement membrane of the kidney
glomeruli, leading to a rapidly progressive glomerulo-
nephritis [3]. Treatments are focused on decreasing in-
flammation induced by circulating antibodies and on
removing these antibodies [4]. Although plasma ex-
change (PE) was effective in removing these antibodies
[5], it unselectively removed all plasma proteins. Thus,
these patients required replacement of human proteins.Table 3 Comparative effects of IA and DFPP on changes
in anti-GBM antibody and IgG concentrations
IA DFPP P
anti-GBM (RU/ml) 141 124 0.452
IgG (g/L) 10.6 8.1 0.049Moreover, PE was associated with inherent risks, includ-
ing anaphylactic reactions, transfusion-related acute
lung injury and transfusion-transmitted infections, in-
cluding infections with hepatitis B and C virus and hu-
man immunodeficiency virus. Furthermore, PE required
large volumes of plasma and was therefore costly, limit-
ing use of this method [6,7].
DFPP was designed to selectively remove the im-
munoglobulin fraction from serum, thus minimizing the
volume of substitution fluid [8]. Unlike PE, DFPP select-
ively removes high-molecular-weight molecules, minim-
izing albumin loss, the need for substitution fluids, and
associated hemodynamic fluctuations [9]. DFPP requires
only 10–15% of the plasma volume required during PE,
greatly reducing the incidence of adverse reactions.
Moreover, using albumin or normal saline instead of
Figure 1 Effects of IA and DFPP on concentrations of anti-GBM antibodies and IgG in individual patients: In DFPP group, the average
reduction of anti-GBM-antibody was 123.7 RU/ml(61.9%), as did the average reduction of IgG was 8.2 g/L(62.7%). Similarly, in the IA
group the average reduction of anti-GBM-antibody was 142 RU/ml(70.8%), as did the average reduction of IgG was 10.6 g/L(82.5%).
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formed even in the absence of plasma.
We found that the concentrations of anti-GBM-antibody
decreased significantly after DFPP procedures, with a mean
decrement of 56.3 ± 22.7%, indicating that DFPP may be
effective at clearing anti-GBM antibodies. In comparison,
IgG concentration declined a mean 67.4 ± 12.3%. After the
first procedure, IgG decreased 37.8 ± 12.4%, whereas
anti-GBM-antibody decreased 24.3 ± 16.0%. Thus, in
agreement with previous findings, we found that a sim-
ple DFPP procedure was more efficient at removing
anti-GBM antibodies than IgG [10]. Moreover, in agree-
ment with previous findings [11], we found that serumTable 4 Adverse effects during DFPP and IA
DFPP group (n = 16) IA group (n = 12) p
Fever 4 2 0.701
Bleeding
Lung 1 1 0.782
Gastrointestinal 0 0 0.302
Skin 1 0 0.622IgG concentration decreased exponentially while serum
anti-GBM antibodies decreased linearly.
None of the patients in the DFPP group experienced se-
vere complications. Four patients had fever during the
course of DFPP, but their temperatures decreased to nor-
mal range after antibiotic therapy. Nevertheless, it was dif-
ficult to determine whether fever was caused by infection
or an allergic reaction. One patient had diffuse alveolar
hemorrhage, as confirmed by chest CT, but without severe
hemoptysis, with the symptoms improving after symp-
tomatic treatment. One study of 335 patients who
underwent a total of 2502 plasmapheresis procedures
during 515 courses of plasmapheresis found that com-
plications during DFPP included hypotension, bleeding
events, allergic reactions, muscle cramps, catheter-related
complications such as vascular trauma and septicemia,
and problems associated with membrane filters such as
hemolysis [12]. That study found that 67.5% of patients
experienced complications, occurring during 26.3% of
procedures and 60.0% of courses of plasmapheresis.
Hemolysis may be the most frequent complication of
DFPP, reported during 20% of procedures. While only 2
Figure 2 The patient survive and the renal survive were compared between the DFPP group and the IA group: the patient survival
was similar. The renal survival of IA group was a little better than the DFPP group, but the difference was no significant between the two groups.
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skin or lungs, slight hemolysis without an obvious de-
crease in hemoglobin (Hb) concentration may have oc-
curred. The mean decrease in Hb following a course of
DFPP was 2 g/L. However, since DFPP could also re-
move fibrinogen, patients undergoing this procedure
may have hypofibrinogenemia. Although this condition
is not associated with bleeding tendency, clinically overt
bleeding has been occasionally reported, especially after
serial plasmapheresis. Moreover, most of our patients
had anemia and were treated with erythropoietin. Be-
cause of the difficulty determining whether DFPP in-
creased internal bleeding, invasive procedures should
not be performed during the course of DFPP and high-
risk patients should be closely monitored during DFPP
treatment. The time required for fibrinogen concentra-
tion to return to pretreatment levels after a single DFPP
session is 3 to 4 days. Therefore, all of our patients were
administered fresh plasma infusions after DFPP to re-
store fibrinogen and prevent bleeding episodes, perhaps
explaining why none of these patients experienced se-
vere hemolysis during the course of DFPP.
Outcomes were similar in the DFPP and IA groups.
We found that 4/16 (25%) patients in the DFPP group
no longer required maintenance renal replacement ther-
apy at the end of follow-up, a lower percentage than pre-
viously reported [13]. Renal injury, however, was more
severe in our patients. For example, the maximum mean
SCr concentration was 826 μmol/l, and the highest SCr
levels in 14 of the 16 patients in this group were higher
than the level indicative of uremia. These 14 patients
therefore required renal replacement therapy at admis-
sion. In addition, although the prognosis of patients with
anti-GBM nephritis would be improved by earlier diag-
nosis and treatment [14-17], the time from disease onset
to admission in our patients ranged from 10 days to
13 months. A comparison of clinical features showedthat patients who progressed to ESRD tended to have a
longer course of disease. Therefore, a longer time from
disease onset to admission is predictive of poorer prog-
nosis. Thus, if the diagnosis is highly suspected, it may
be appropriate to begin plasmapheresis while awaiting
confirmation. The titer of circulating anti-GBM antibody
is not the only determinant of the degree of renal injury.
Complement components and proteases are involved in
the process of renal injury following the binding of anti-
GBM antibody to GBM.
Compared with patients in a previous study [18], our
patients had more severe lesions histopathologically.
Seven of the 16 (43.8%) patients had >85% crescent forma-
tion, indicative of a poor outcome [19,20]. A comparison
of the pathological features in patients with different out-
comes showed that patients who progressed to ESRD
tended to have more crescent formation, especially fibro-
cellular/fibrous crescents. Taken together, all of the factors
cited above may affect the prognosis of renal function and
may explain why outcomes in our DFPP group were not
better than previously reported [21]. Moreover, urine in-
creased in three patients after DFPP therapy.
Correlation analysis showed that outcomes were sig-
nificantly and negatively corrected with formation of
crescents (r = −0.462, P = 0.008) and fibrocellular/fibrous
crescents (r = −0.376, P = 0.034), with peak SCr concen-
tration (r = −0.495, P = 0.004), and with the course of
kidney disease (r = −0.393, P = 0.015). The predictors of
kidney survival in patients with anti-GBM GN were
found to include the percentage of glomerular crescents
and SCr concentration and need for dialysis at presenta-
tion. We found that all of our patients with an initial
SCr >500 μmol/L and 85–100% glomerular crescents be-
came chronically dialysis-dependent despite aggressive
treatment.
We found that patient survival was good and kidney
survival moderate, suggesting that, unless there was
Zhang et al. BMC Nephrology 2014, 15:128 Page 7 of 7
http://www.biomedcentral.com/1471-2369/15/128evidence of pulmonary hemorrhage, which indicates a
very high risk of death, patients with high initial SCr
and crescent formation do not require DFPP or IA.
While for the patients with a higher percentage of fresh
cellular crescents should be treated with DFPP to re-
move anti-GBM antibodies, thus avoiding further dam-
age. This is particularly applicable to patients with high
serum concentrations of anti-GBM antibodies.
Conclusion
Compared with IA, DFPP could effectively and safely
clear anti-GBM antibodies and to some extent improve
renal symptoms. DFPP may be a better choice for the
treatment of anti-GBM disease, especially if IA columns
and plasma are insufficient. DFPP resulted in good pa-
tient survival and moderate kidney survival. Except for
patients with pulmonary hemorrhage requiring active
plasma therapy, complications during DFPP may be de-
creased by reducing the number of procedures in pa-
tients with SCr >500 μmol/L and severe chronic renal
histology, especially those with a long course of disease.
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